University of Michigan Rogel Cancer Center: Lung Neoplasms trials

The registry lists 14 Lung Neoplasms studies with University of Michigan Rogel Cancer Center as lead sponsor. 2 are open to participants now and 5 have results posted.

Early Phase 1 2Phase 1 2Phase 2 6No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer PatientsRecruitingNCT07291414Not applicable
• Gilteritinib for the Treatment of ALK NSCLCRecruitingNCT06225427Phase 1
• Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted AgentsCompletedNCT03242915Phase 2Results posted
• Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung CancerTerminatedNCT03228186Phase 2Results posted
• Using FDG-PET During Radiation Therapy in Non-Small Cell Lung CancerCompletedNCT01190527Not applicableResults posted
• Phase I/II Calcitriol in Lung CancerTerminatedNCT00794547Phase 1/2Results posted
• Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLCCompletedNCT00616109Phase 2Results posted
• A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLCCompletedNCT02463994Early Phase 1
• Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver MutationsWithdrawnNCT02277457Early Phase 1
• A Multi-Centered Trial Evaluating the Role of Vitamin D Metabolism in Non-Small Cell Lung CancerTerminatedNCT01409681
• UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With CancerCompletedNCT00900094
• Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung CancerCompletedNCT00603057
• Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression ProfilingTerminatedNCT00161278Phase 2
• Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLCCompletedNCT00156286Phase 2